Lytic phage potentiates aztreonam–avibactam in Escherichia coli with layered resistance by disrupting adaptive stress tolerance

In the ongoing battle against bacterial infections, doctors face a formidable opponent: bacteria that have learned to ignore our most powerful medicines. For decades, we have relied on antibiotics to kill these invaders, but bacteria evolve rapidly, developing layers of defense that render drugs useless. One common strategy bacteria use is to build walls that keep drugs out or pump them back out before they can work. When a bacterium carries multiple such defenses, it becomes a "superbug," capable of surviving treatments that would kill ordinary bacteria. Scientists have long hoped that combining different types of attacks might break through these defenses. One promising idea involves pairing antibiotics with bacteriophages, which are viruses that naturally infect and kill bacteria. While antibiotics attack the cell's machinery, phages act like tiny predators that latch onto the surface, inject their genetic material, and burst the cell open. The hope is that these two forces might work better together than apart, creating a synergy that overwhelms the bacteria's defenses.

A team of researchers at Karolinska Institutet in Sweden recently put this idea to the test against a particularly stubborn strain of Escherichia coli. This specific bacterium was a triple threat: it produced an enzyme that destroys many antibiotics, had a mutation that changed the target the drug was supposed to hit, and lacked a key doorway in its outer wall that usually lets medicine enter. The researchers paired this superbug with a lytic phage, a virus that kills bacteria by bursting them, and a specific antibiotic combination called aztreonam–avibactam. They wanted to see if the virus could make the antibiotic work again, even at low doses where the drug usually fails. What they discovered was not a simple case of the virus opening a door for the drug, but rather a more complex and temporary breakdown of the bacteria's ability to cope with stress.

The experiment began by exposing the bacteria to the antibiotic alone, the virus alone, and a mix of both. When the bacteria faced the antibiotic by itself, they survived well at low doses, only dying when the drug concentration was very high. When faced with the virus alone, the bacteria were initially killed in large numbers, but a small group of survivors quickly grew back, having developed resistance to the virus. However, when the researchers mixed the virus with a low dose of the antibiotic, the result was dramatic. The bacteria were wiped out much more effectively than with either treatment alone. This "killing window" was most intense between four and six hours after exposure, where the combination reduced the bacterial population by about 10,000 times compared to the antibiotic alone. To understand what was happening inside the cells during this critical moment, the scientists measured the bacteria's metabolic heat and read their genetic activity at one hour, four hours, and twenty-four hours.

The measurements revealed that the combination treatment did something unique to the bacteria's internal state. While the antibiotic alone or the virus alone caused the bacteria to activate various survival programs, the combination prevented these programs from working properly. Specifically, the bacteria failed to switch on the backup systems they normally use to handle stress. Under normal attack, bacteria can reroute their energy to alternative pathways, repair damaged proteins, and neutralize harmful chemicals. But when hit by both the virus and the drug at the same time, these rescue mechanisms collapsed. The bacteria could not ramp up their defenses fast enough to handle the double pressure. It was as if the stress of the virus infection overloaded the bacteria's internal repair shop, leaving them unable to fix the damage caused by the antibiotic.

Crucially, the researchers ruled out several other possibilities that might have explained this success. They looked closely at the bacteria's outer wall to see if the virus had somehow opened up the blocked doorways, allowing more drug to enter. The data showed that the main doorways remained closed, and the virus did not restore the bacteria's ability to let the drug in. They also checked if the bacteria had turned off the pumps that usually eject the drug, but found that these pumps were not the key factor either. Instead, the evidence pointed to a temporary failure of the bacteria's stress tolerance. The virus did not genetically reprogram the bacteria to become weak; rather, the simultaneous attack simply pushed the bacteria past their limit. The bacteria were still capable of resistance, but for a few critical hours, they were too overwhelmed to use it.

This finding suggests a new way to think about treating difficult infections. The power of the combination did not come from permanently fixing the bacteria or reversing their resistance genes. Instead, it created a fleeting moment where the bacteria's defenses were too strained to hold. The virus acted as a second pressure that, when combined with the antibiotic, caused the bacteria's stress-management systems to fail. This "functional resensitization" means that even bacteria with multiple layers of resistance can be killed if the treatment can overwhelm their ability to cope. While this study focused on a single strain of bacteria in a laboratory setting, the results offer a clear path forward. They suggest that finding the right pair of virus and drug could allow doctors to use lower doses of antibiotics to kill superbugs, provided the combination can disrupt the bacteria's ability to buffer stress. The work highlights that in the war against superbugs, the key may not be finding a stronger weapon, but rather finding a way to make the enemy's defenses collapse under the weight of a coordinated attack.